Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Scientific Reports|May 8, 2020
Proteomics-Based Approach Identifies Altered ER Domain Properties by ALS-Linked VAPB MutationTomoyuki Yamanaka, Risa Nishiyama, Tomomi Shimogori, et al.In Vivo (Athens, Greece)|December 31, 2024
Bortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-upRisa Nishiyama, Toshiya Kagoo, Hironori Ueno, et al.The Journal of Experimental Medicine|February 25, 2022
Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegenerationKazuhisa Ishida, Kaoru Yamada, Risa Nishiyama, et al.International Journal of Clinical Oncology|January 8, 2026
Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in JapanTetsuro Ochi, Shinichi Makita, Anna Hiratsuka, et al.Journal of Clinical and Experimental Hematopathology : JCEH|September 28, 2025
Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphomaRisa Nishiyama, Shinichi Makita, Mika Shiotsuka, et al.Transplantation and Cellular Therapy|July 1, 2026
Real-world use of maribavir for refractory CMV infection and intolerance to conventional anti-CMV agents after allogeneic hematopoietic cell transplantationRisa Nishiyama, Ayumu Ito, Yu Akahoshi, et al.International Journal of Hematology|May 12, 2026
T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucelRisa Nishiyama, Anna Hiratsuka, Tetsuro Ochi, et al.International Journal of Clinical Oncology|April 12, 2026
Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphomaRisa Nishiyama, Shinichi Makita, Anna Hiratsuka, et al.Pageof 1